Cencora stock rises 6% to $341.69, lagging S&P 500 gains
Cencora shares climbed 6% to $341.69 over the past six months, a performance that trailed the 9.7% gain recorded by the S&P 500 during the same period. The stock moved in close alignment with broader market trends, reflecting a period of steady appreciation for the pharmaceutical distribution firm.
Cencora shares climbed 6% to $341.69 over the past six months, a performance that trailed the 9.7% gain recorded by the S&P 500 during the same period. The stock moved in close alignment with broader market trends, reflecting a period of steady appreciation for the pharmaceutical distribution firm.
Cencora, formerly known as AmerisourceBergen, completed a rebranding in 2023. The company operates globally, connecting manufacturers with healthcare providers while supplying logistics, data analytics, and consulting services. Its business model relies heavily on volume, a characteristic common among health insurance and distribution providers that operate with low margins.
With $332.8 billion in revenue generated over the past 12 months, Cencora stands as one of the largest enterprises in the healthcare sector. This scale allows the company to spread fixed costs, such as infrastructure and administration, across a higher volume of goods. Such economies of scale can reduce the cost per unit and potentially enhance bargaining power with suppliers.
Financial metrics indicate that Cencora’s expansion has been profitable on a per-share basis. The company’s earnings per share grew at a compounded annual rate of 14.4% over the last five years. This outpaced its annualized revenue growth rate of 10.2% over the same timeframe, suggesting an improvement in profitability as the business expanded.
The company’s capital efficiency is also notable. Cencora’s five-year average return on invested capital stood at 50.2%, a figure that places it among the top performers in the healthcare industry. This metric reflects the operating profit generated relative to the capital raised through debt and equity.
At its current price of $341.69, Cencora trades at a forward price-to-earnings ratio of 17.4 times. StockStory, which published an analysis of the stock, noted that Cencora ranks highly on its internal lists due to these fundamental characteristics. The firm encourages investors to review its full research report to determine if now is an appropriate time to initiate a position in the stock.
In a separate promotional section, StockStory highlighted its AI-driven stock screening system. The firm stated that its system identified Palantir before it rose 1,662% between October 2022 and February 2026. It also flagged AppLovin prior to a 753% increase between February 2024 and February 2026, and Nvidia before it gained 1,178% between January 2023 and February 2026. The company produces six new stock recommendations weekly that pass specific tests.